Hubbry Logo
Fragment crystallizable regionFragment crystallizable regionMain
Open search
Fragment crystallizable region
Community hub
Fragment crystallizable region
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Fragment crystallizable region
Fragment crystallizable region
Fragment crystallizable region
View on Wikipedia
from Wikipedia
An antibody digested by papain yields three fragments, two Fab fragments and one Fc fragment
An antibody digested by pepsin yields two fragments: a F(ab')2 fragment and a pFc' fragment

The fragment crystallizable region (Fc region) is the tail region of an antibody that interacts with cell surface receptors called Fc receptors and some proteins of the complement system. This region allows antibodies to activate the immune system, for example, through binding to Fc receptors. In IgG, IgA and IgD antibody isotypes, the Fc region is composed of two identical protein fragments, derived from the second and third constant domains of the antibody's two heavy chains; IgM and IgE Fc regions contain three heavy chain constant domains (CH domains 2–4) in each polypeptide chain.[1][2] The Fc regions of IgGs bear a highly conserved N-glycosylation site.[3][4] Glycosylation of the Fc fragment is essential for Fc receptor-mediated activity.[5] The N-glycans attached to this site are predominantly core-fucosylated diantennary structures of the complex type. In addition, small amounts of these N-glycans also bear bisecting GlcNAc and α-2,6 linked sialic acid residues.[3]

The other part of an antibody, called the Fab region, contains variable sections that define the specific target that the antibody can bind. By contrast, the Fc region of all antibodies in a class are the same for each species; they are constant rather than variable. The Fc region is, therefore, sometimes incorrectly termed the "fragment constant region".

Fc binds to various cell receptors and complement proteins. In this way, it mediates different physiological effects of antibodies (detection of opsonized particles; cell lysis; degranulation of mast cells, basophils, and eosinophils; and other processes).[6]

Engineered Fc fragments

[edit]

In a new development in the field of antibody-based therapeutics, the Fc region of immunoglobulins has been engineered to contain an antigen-binding site.[7] This type of antigen-binding fragment is called Fcab. Fcab fragments can be inserted into a full immunoglobulin by swapping the Fc region, thus obtaining a bispecific antibody (with both Fab and Fcab regions containing distinct binding sites). These bispecific monoclonal antibodies are sometimes referred to as mAb2.[8]

See also

[edit]

References

[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Fragment crystallizable region

View on Grokipedia
from Grokipedia
The fragment crystallizable (Fc) region is the constant, tail-like portion of an molecule, formed by the paired C-terminal domains of the heavy chains (CH2 and CH3 in IgG isotypes), which links the antibody to immune effector cells and complement proteins to mediate downstream immune responses. This region, connected to the antigen-binding Fab arms via a flexible hinge sequence, typically spans about 50 kDa and includes a conserved N-linked glycan at 297 (N297) that influences its interactions. The Fc region was first isolated and characterized in 1959 by Rodney R. Porter, who used enzymatic digestion of rabbit γ-globulin to separate it from the antigen-binding fragments, noting its unexpected ability to crystallize and naming it "Fc" accordingly; this work laid the foundation for understanding antibody structure and earned Porter the 1972 in Physiology or Medicine, shared with . Functionally, the Fc region recruits immune cells through binding to Fcγ receptors (FcγRs) on leukocytes, enabling (ADCC), (ADCP), and other effector mechanisms that eliminate pathogen-infected or aberrant cells. It also activates the via interaction with C1q, promoting (CDC) and opsonization. Additionally, the Fc region binds the neonatal Fc receptor (FcRn) in a pH-dependent manner, which protects antibodies from lysosomal degradation and extends their serum half-life, a property exploited in Fc-fusion therapeutics to enhance drug persistence. Variations in Fc sequence across immunoglobulin isotypes (e.g., IgG1 vs. IgG4) dictate specific effector profiles, with IgG1 exhibiting strong ADCC and CDC activity due to high-affinity FcγRIIIa binding. In modern engineering, the Fc domain is frequently modified—such as through mutations at key residues like (L234A/L235A) or afucosylation—to silence or enhance these functions for optimized therapeutic efficacy in cancer, autoimmune diseases, and infectious contexts.

Structure and Composition

Domains and Organization

The fragment crystallizable (Fc) region of an (IgG) consists of the two CH2 and two CH3 constant domains contributed by the heavy chains, forming a homodimeric structure that was first isolated and characterized by Rodney Porter in 1959 through enzymatic digestion with . This Fc fragment is generated by digestion, which cleaves the in the upper hinge region, yielding a crystallizable portion that dimerizes via two interchain bonds located in the upper hinge and stabilized by non-covalent interactions at the CH2-CH2 and CH3-CH3 interfaces. In the overall Y-shaped architecture of the , the Fc region constitutes the stem, providing a symmetric constant framework that contrasts with the variable Fab arms responsible for binding, thereby enabling the Fc to serve as a scaffold for immune effector interactions. The CH2 domains, positioned adjacent to the , each contain approximately 110 and exhibit a lower stability compared to the CH3 domains, with unfolding temperatures around 65–70°C in isolation. The CH3 domains, located at the C-terminal end, are more stable (unfolding around 80–85°C) and mediate dimerization through extensive hydrophobic contacts and salt bridges involving residues such as Phe405, Tyr407, and Lys409 in the AB and EF loops. A key feature contributing to Fc stability and folding is the conserved N-linked site at 297 (Asn297) in each CH2 domain, where a biantennary complex glycan is attached, occupying the interdomain space between the CH2 domains to prevent steric clashes and enhance conformational rigidity. This modulates the CH2 domain's folding kinetics and increases its melting temperature by approximately 4–5°C, as demonstrated in studies replacing the glycan sequon. The glycans also influence non-covalent interactions at the CH2-CH3 interface, involving residues like Pro329 and Pro331, which help propagate structural stability across the Fc. Variations in domain organization exist among IgG subclasses, particularly in the CH3-CH3 interface, which affects overall Fc stability. In human IgG1, the interface features a stabilizing between Asp399 on one chain and Lys409 on the other, promoting tight dimerization with dissociation constants below 10^{-10} M. In contrast, IgG4 substitutes Arg for Lys at position 409, weakening this interaction and reducing interface stability by over 100-fold, which can lead to partial dissociation under physiological conditions. These subclass-specific differences in residues at the domain interfaces, such as variations in the FG loop of CH3, fine-tune the Fc's structural framework without altering the core beta-sheet topology.

Hinge Region

The hinge region of the fragment crystallizable (Fc) portion in antibodies consists of a flexible polypeptide segment rich in residues, which imparts conformational adaptability, and features interchain bonds that link the two heavy chains for . This segment, located between the CH1 domain of the Fab arms and the CH2 domain of the Fc, typically includes a core motif such as Cys-Pro-Pro-Cys-Pro in IgG1, where the cysteines form two inter-heavy bonds to maintain dimerization. The content, often comprising around 33% of the sequence in IgG1, promotes a poly II that balances rigidity and flexibility. In IgG subclasses, the displays significant variations in and to modulate flexibility and function. IgG1 has a 15-amino-acid divided into three parts: the upper ( EPKSCDKTHT), which enables Fab arm rotation; the core (CPPCP), rich in prolines and hosting the bonds; and the lower , which interfaces with the CH2 domain. In contrast, IgG2 and IgG4 feature shorter 12-amino-acid s with two bonds each, while IgG3 possesses an extended 62-amino-acid with 11 bonds and duplicated proline-rich motifs (e.g., 21 repeats of Pro-X-Pro patterns), resulting in greater overall flexibility ordered as IgG3 > IgG1 > IgG4 > IgG2 across subclasses. These differences arise from single exons in IgG1, IgG2, and IgG4 versus multiple exons in IgG3, influencing the spatial separation between Fab and Fc regions. The hinge's flexibility permits independent movement of the Fab arms, allowing them to reorient for optimal bivalent binding, where the two Fabs can engage separate epitopes simultaneously despite varying distances or angles on the surface. This dynamic property arises from hinge bending and torsional motions, enabling the to adapt to crowded or complex environments without compromising Fc positioning. The lower 's connection to the CH2 domain briefly supports this by allowing limited Fc sway, which can enhance effector function accessibility. Evolutionarily, the hinge region is conserved across immunoglobulin classes for its core role in providing Fab-Fc linkage and flexibility, though sequences show hypervariability, particularly in the upper and core segments, to evolve adaptive responses against pathogens, as seen in primate IgA hinges under positive selection. Mutations in the hinge can compromise stability; for instance, truncations reduce aggregation propensity and improve stability by minimizing exposed flexible regions, while substitutions like those preventing reduction (e.g., in IgG4) enhance resistance to cleavage and maintain structural integrity under physiological stress.

Biological Functions

Effector Mechanisms

The fragment crystallizable (Fc) region of antibodies mediates key effector mechanisms that bridge adaptive and innate immunity, enabling the recruitment and activation of immune cells and complement proteins to eliminate antibody-bound targets. These functions primarily involve interactions with Fc gamma receptors (FcγRs) on effector cells and the complement component C1q, leading to processes such as and . Antibody-dependent cellular cytotoxicity (ADCC) is initiated when the Fc region of IgG antibodies, particularly IgG1, binds to the activating FcγRIIIa receptor on natural killer (NK) cells, triggering the release of cytotoxic granules containing perforin and granzymes that lyse the target cell. This mechanism is crucial for antitumor and antiviral responses, with the and CH2 domains of the Fc region facilitating the receptor interaction. Complement-dependent cytotoxicity (CDC) occurs through the binding of the complement protein C1q to the CH2 domains of the Fc region on clustered IgG molecules, activating the classical complement pathway and forming the membrane attack complex (MAC) that perforates target cell membranes. This process requires multimeric antibody binding to antigens for effective C1q recruitment and is most efficient with IgG1 and IgG3 subclasses due to their strong C1q affinity. Antibody-dependent cellular phagocytosis (ADCP) involves the Fc region engaging activating FcγRs, such as FcγRIIa, on phagocytic cells like macrophages and neutrophils, promoting the engulfment and lysosomal degradation of opsonized targets. This pathway enhances clearance of pathogens and tumor cells, with IgG1 demonstrating robust activity through its balanced FcγR binding profile. Effector potency varies significantly among human IgG subclasses: IgG1 exhibits strong ADCC, ADCP, and CDC due to high-affinity interactions with FcγRIIIa, FcγRIIa, and C1q; IgG3 is similarly potent but less stable; IgG2 shows moderate ADCP via selective FcγRIIa binding but weak ADCC and CDC; and IgG4 has minimal effector activity, lacking significant binding to most FcγRs or C1q, making it suitable for non-cytotoxic applications.

Interactions with Fc Receptors

The fragment crystallizable (Fc) region of immunoglobulin G (IgG) antibodies interacts with activating Fcγ receptors (FcγRs) on immune cells to initiate pro-inflammatory responses. These receptors include FcγRI, which exhibits high-affinity binding to monomeric IgG-Fc with dissociation constants (K_D) in the range of 10^{-9} to 10^{-10} M, and low-affinity receptors such as FcγRIIa and FcγRIIIa, which bind IgG-Fc with K_D values of 10^{-5} to 10^{-7} M and typically require multimeric immune complexes for effective engagement. FcγRI is predominantly expressed on monocytes, macrophages, and dendritic cells, while FcγRIIa is found on neutrophils, macrophages, and platelets, and FcγRIIIa on natural killer (NK) cells and macrophages. These interactions occur primarily through the CH2 domain of the Fc region, where specific residues and structural conformations facilitate receptor docking. In contrast, the inhibitory receptor FcγRIIb counterbalances these activating signals to prevent excessive immune activation and maintain . Expressed on , macrophages, and dendritic cells, FcγRIIb binds IgG-Fc with low affinity similar to other low-affinity FcγRs but signals through an immunoreceptor tyrosine-based inhibitory motif (ITIM) that recruits phosphatases like SHIP1 to dampen ITAM-mediated activation from co-engaged activating FcγRs or receptors. This inhibitory function is crucial for regulating antibody production, suppressing release, and limiting , as deficiencies in FcγRIIb lead to heightened inflammatory responses in experimental models. The ratio of activating to inhibitory FcγR engagement determines the net immune outcome, with FcγRIIb often co-ligated by immune complexes to fine-tune responses. The molecular basis of these interactions centers on epitopes within the lower hinge-proximal region of the CH2 domain, involving residues such as Asp265, Glu233, and Pro329, which form salt bridges and hydrogen bonds with FcγR extracellular domains. N-linked at Asn297 in the CH2 domain profoundly influences binding affinity; afucosylated or agalactosylated glycans promote an "open" Fc conformation that enhances interactions with activating FcγRs like FcγRIIIa by up to 50-fold, whereas sialylated glycans induce a "closed" state that reduces affinity for these receptors while potentially favoring type II FcγRs. These glycan modifications thus modulate the specificity and strength of Fc-FcγR binding without altering the core protein interface. Distinct from classical FcγRs, the neonatal Fc receptor (FcRn) binds IgG-Fc in a pH-dependent manner, with high affinity (nanomolar K_D) at acidic pH (~6.0-6.5) in endosomes and negligible binding at neutral pH (~7.4) on cell surfaces, primarily through interfaces spanning the CH2-CH3 domains.

Role in Antibody Half-Life

The neonatal Fc receptor (FcRn) plays a pivotal role in extending the serum half-life of immunoglobulin G (IgG) antibodies by protecting them from lysosomal degradation through a pH-dependent recycling mechanism. Circulating IgG molecules are internalized by endothelial cells via pinocytosis and trafficked into acidic endosomes, where the pH drops to approximately 6.0. At this acidic pH, the Fc region of IgG binds with high affinity to FcRn, which is expressed on the endosomal membrane, thereby diverting the antibody away from proteolytic degradation in lysosomes. The FcRn-IgG complex is then recycled back to the cell surface, where the neutral pH of the bloodstream (approximately 7.4) causes dissociation, releasing the IgG into circulation to continue its function. This bidirectional pH sensitivity ensures efficient salvage and reuse of IgG, preventing its rapid clearance. The interaction between FcRn and the Fc region occurs primarily at the interface between the CH2 and CH3 domains, involving specific residues that confer pH dependence. Critical residues in the IgG Fc, such as His310 in the CH2 domain and His435 in the CH3 domain, become protonated at acidic pH, forming bonds and electrostatic interactions with negatively charged residues on FcRn, like Asp137 and Glu117. Ile253 in the CH2 domain also contributes to hydrophobic contacts stabilizing the complex. Variations in these residues across IgG subclasses influence binding affinity; for instance, human IgG1 exhibits stronger FcRn interaction compared to IgG3 due to subtle differences at the interface, leading to differential efficiencies. IgG2 and IgG4 show intermediate affinities, underscoring how subclass-specific features modulate without altering other effector properties. This FcRn-mediated recycling significantly impacts the of therapeutic , allowing less frequent dosing and improved efficacy in clinical settings. Human IgG1, the most commonly used subclass in therapeutics, has a serum of approximately 21 days, largely attributable to robust FcRn binding and recycling. Disruptions in this interaction, such as through mutations at key residues, can reduce by up to 50%, highlighting the therapeutic importance of preserving native FcRn affinity during antibody design. Evolutionarily, the FcRn-IgG interaction provides a key advantage in sustaining by maintaining long-term levels in the bloodstream, enabling prolonged protection against pathogens. This mechanism likely originated to facilitate maternal IgG transfer across the or via in mammals, ensuring neonatal immunity before the offspring's own adaptive response matures. By recycling IgG and —another FcRn —FcRn optimizes resource allocation in the , conserving energy for production while extending the duration of protective responses. This persistence supports the maintenance of memory B cell-derived antibodies, contributing to immunological and host defense over extended periods.

Engineering and Modifications

Engineered Fc Fragments

The fragment crystallizable (Fc) region was first isolated in 1959 through limited of IgG using , a method developed by Rodney Porter that yielded two antigen-binding Fab fragments and a single Fc fragment capable of , earning it the designation "fragment crystallizable." This enzymatic approach, involving digestion above the hinge region followed by purification via , marked the beginning of Fc fragment production for structural and functional studies in the . Porter's work laid the foundation for understanding the modular architecture of antibodies and enabled early crystallographic analyses of the Fc domain. Traditional production of Fc fragments relied on papain or pepsin digestion of polyclonal or monoclonal IgG, with papain cleaving above the hinge to produce intact Fc dimers while pepsin generates F(ab')2 and smaller Fc pieces. However, these methods suffer from variability due to batch-to-batch differences in starting antibodies and incomplete digestion, prompting the shift to recombinant expression systems starting in the 1980s. Recombinant Fc-only constructs are now generated by cloning the DNA encoding the CH2 and CH3 domains (with or without the hinge) into expression vectors, typically expressed in mammalian cell lines like Chinese hamster ovary (CHO) or human embryonic kidney (HEK293) cells for proper glycosylation and folding. Bacterial systems such as Escherichia coli are used for non-glycosylated variants, while yeast offers intermediate scalability; these methods yield high-purity, soluble Fc dimers at gram-scale for research purposes. Soluble recombinant Fc dimers, lacking the Fab arms, serve as versatile tools in , particularly for and immunological assays. In structural studies, these dimers facilitate high-resolution and cryo-electron of the Fc region, revealing atomic details of its dimer interface and receptor-binding sites, as demonstrated in the 1.9 Å of human IgG1 Fc. They also function as decoy molecules to saturate Fc receptors on immune cells, preventing non-specific binding of Fc-containing probes in techniques like and ; for instance, pre-incubation with 1-5 µg/mL recombinant human IgG1 Fc effectively blocks Fcγ receptors on monocytes and macrophages. This decoy role enhances specificity without altering native Fc interactions. To enhance binding avidity, engineers have developed multimeric Fc constructs by fusing multiple Fc domains via flexible linkers or oligomerization motifs, building on the natural dimeric form. A prominent example is hexa-Fc, a hexameric assembly of six IgG1 Fc units created through C-terminal fusion to a trimerization domain from cartilage matrix protein, resulting in a structure with threefold higher for low-affinity Fcγ receptors compared to monomeric Fc. These multimers, produced recombinantly in mammalian cells, mimic the multivalent engagement of and exhibit up to 100-fold increased potency in receptor crosslinking, as shown in binding assays with FcγRIIb. Such designs represent a from early crystallographic tools to advanced biomolecular scaffolds.

Therapeutic Applications

The fragment crystallizable (Fc) region of monoclonal antibodies (mAbs) is frequently engineered in therapeutic contexts to modulate effector functions and , thereby enhancing efficacy while minimizing adverse effects such as release or off-target immune activation. These modifications target interactions with Fcγ receptors (FcγRs) for (ADCC) and (CDC), or with the neonatal Fc receptor (FcRn) for extension, allowing tailored profiles for , autoimmune diseases, and infectious conditions. For instance, in cancer therapies, augmenting ADCC can improve tumor cell killing, while in autoimmune treatments, silencing effector functions prevents unintended tissue damage. To enhance ADCC and CDC, specific substitutions in the IgG1 Fc, such as S239D/I332E/A330L, increase binding affinity to activating FcγRs like FcγRIIIa while reducing interaction with the inhibitory FcγRIIb. This triple demonstrates up to 100-fold greater potency in ADCC assays compared to wild-type IgG1, promoting more effective of killer cells and complement activation against target cells. An approved example is margetuximab (Margenza), an anti-HER2 mAb that incorporates a distinct set of five Fc mutations (L235V, F243L, R292P, Y300L, P396L) to enhance binding to FcγRIIIa across polymorphisms, which showed superior in HER2-positive patients when combined with versus . Conversely, silent Fc variants abrogate effector functions to improve safety in therapies where immune activation is undesirable, such as blocking antibodies for autoimmune disorders. The L234A/L235A () mutations in the lower region of IgG1 disrupt FcγR and C1q binding, reducing ADCC and CDC by over 95% without altering specificity. Often combined with P329G for complete silencing (LALA-PG), this approach is used in various investigational antibodies. A related silencing strategy is exemplified in (Tecentriq), an anti-PD-L1 mAb that employs the N297A mutation to eliminate N-linked and abolish FcγR and C1q interactions, thereby minimizing FcγR-mediated depletion of antigen-presenting cells, enhancing checkpoint inhibition while avoiding excessive . In autoimmune contexts, (Humira), an anti-TNF IgG1 with native Fc, relies on non-effector blockade but highlights how unmodified Fcs can suffice when effector silencing is not required, though engineered silent variants are increasingly adopted to mitigate risks like infusion reactions. Half-life extension through FcRn affinity tuning prolongs serum persistence, reducing dosing frequency and improving patient compliance in chronic therapies. The M252Y/S254T/T256E (YTE) triple enhances pH-dependent FcRn binding at acidic endosomal , extending IgG by 3-4 fold in humans, from ~21 days to up to 80-100 days. This variant increases recycling efficiency post-endocytosis, as demonstrated in early studies with motavizumab-YTE, an anti-RSV mAb. A clinically approved application is (Beyfortus), an anti-RSV mAb with YTE modification, which provides extended protection in infants with a single dose, achieving extension to ~70 days and reducing hospitalizations by 75% in phase 3 trials. Recent advances as of 2023 include , a bispecific T-cell engager with Fc enhancements for improved ADCC, approved for relapsed/refractory .

References

  1. https://www.ncbi.nlm.nih.gov/books/NBK27144/
  2. https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/fragment-crystallizable-region
  3. https://pmc.ncbi.nlm.nih.gov/articles/PMC1197021/
  4. https://pmc.ncbi.nlm.nih.gov/articles/PMC7709126/
  5. https://pubmed.ncbi.nlm.nih.gov/25712466/
  6. https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/fragment-crystallizable-fragment
  7. https://pmc.ncbi.nlm.nih.gov/articles/PMC3338938/
  8. https://www.biointron.com/blog/role-of-fab-and-fc-regions-in-antibody-function.html
  9. https://pmc.ncbi.nlm.nih.gov/articles/PMC4852379/
  10. https://pmc.ncbi.nlm.nih.gov/articles/PMC3469823/
  11. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1188838/full
  12. https://www.biointron.com/blog/role-of-fc-glycans-in-antibody-function.html
  13. https://www.jbc.org/article/S0021-9258%2820%2944070-0/fulltext
  14. https://link.springer.com/article/10.1007/s42452-025-07625-7
  15. https://www.sciencedirect.com/topics/medicine-and-dentistry/hinge-region
  16. https://www.mdpi.com/2073-4468/8/4/55
  17. https://www.tandfonline.com/doi/full/10.1080/19420862.2021.1882028
  18. https://pmc.ncbi.nlm.nih.gov/articles/PMC4202688/
  19. https://www.sciencedirect.com/science/article/pii/S096921260400053X
  20. https://journals.plos.org/ploscompbiol/article?id=10.1371/journal.pcbi.1004752
  21. https://www.tandfonline.com/doi/full/10.1080/19420862.2017.1367074
  22. https://pubmed.ncbi.nlm.nih.gov/2120447/
  23. https://academic.oup.com/mbe/article/19/7/1093/1068588
  24. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1389494/full
  25. https://pmc.ncbi.nlm.nih.gov/articles/PMC7603375/
  26. https://www.nature.com/articles/s12276-019-0345-9
  27. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1304365/full
  28. https://pubmed.ncbi.nlm.nih.gov/3258649/
  29. https://jhoonline.biomedcentral.com/articles/10.1186/s13045-020-00876-4
  30. https://pmc.ncbi.nlm.nih.gov/articles/PMC7556827/
  31. https://pmc.ncbi.nlm.nih.gov/articles/PMC4548051/
  32. https://pmc.ncbi.nlm.nih.gov/articles/PMC4148599/
  33. https://pmc.ncbi.nlm.nih.gov/articles/PMC7228307/
  34. https://pmc.ncbi.nlm.nih.gov/articles/PMC3225846/
  35. https://pmc.ncbi.nlm.nih.gov/articles/PMC4451002/
  36. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2019.01540/full
  37. https://www.cell.com/structure/pdf/S0969-2126%2898%2900008-2.pdf
  38. https://academic.oup.com/jimmunol/article/184/4/1968/8007387
  39. https://www.pnas.org/doi/10.1073/pnas.1408766112
  40. https://www.nature.com/articles/s41577-022-00821-1
  41. https://www.sciencedirect.com/topics/medicine-and-dentistry/fragment-crystallizable-fragment
  42. https://pmc.ncbi.nlm.nih.gov/articles/PMC149433/
  43. https://www.evitria.com/journal/recombinant-antibodies/recombinant-antibody-production/
  44. https://pubmed.ncbi.nlm.nih.gov/28620050/
  45. https://www.nature.com/articles/s42003-018-0149-9
  46. https://www.tandfonline.com/doi/full/10.1080/19420862.2024.2406539
  47. https://onlinelibrary.wiley.com/doi/full/10.1111/imr.13394
  48. https://www.pnas.org/doi/10.1073/pnas.0508123103
  49. https://jamanetwork.com/journals/jamaoncology/fullarticle/2775599
  50. https://pmc.ncbi.nlm.nih.gov/articles/PMC9817862/
  51. https://pmc.ncbi.nlm.nih.gov/articles/PMC11659930/
  52. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2019.01296/full
  53. https://academic.oup.com/proteincell/article/9/1/63/6768230
  54. https://pubmed.ncbi.nlm.nih.gov/16793771/
  55. https://pmc.ncbi.nlm.nih.gov/articles/PMC10610324/
  56. https://www.globenewswire.com/news-release/2025/09/23/3154927/28124/en/Fc-and-Glycoengineered-Antibodies-Market-Report-2025-Antibody-Therapeutics-Surge-with-550-Clinical-Pipeline-Molecules-Fc-Innovations-Leading-the-Charge.html
Add your contribution
Related Hubs
User Avatar
No comments yet.